Antimicrobial peptide exposure selects for Staphylococcus aureus resistance to human defence peptides

Journal of Antimicrobial Chemotherapy

Volumn 72, Issue 1, 2017, Pages 115-127

  Kubicek Sutherland, Jessica Z ^a   Lofton, Hava ^a   Vestergaard, Martin ^b   Hjort, Karin ^a   Ingmer, Hanne ^b   Andersson, Dan I ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; CEFTAROLINE; CHLORAMPHENICOL; CLINDAMYCIN; COTRIMOXAZOLE; DAPTOMYCIN; DOXYCYCLINE; ERYTHROMYCIN; GENTAMICIN; HISTONE; HUMAN DEFENSE PEPTIDE; LINEZOLID; PEPTIDE DERIVATIVE; POLYMYXIN; POLYPEPTIDE ANTIBIOTIC AGENT; PR 39; RIFAMPICIN; TEICOPLANIN; TETRACYCLINE; TIGECYCLINE; UNCLASSIFIED DRUG; VANCOMYCIN; WHEAT GERM HISTONE; ANTIINFECTIVE AGENT; ANTIMICROBIAL CATIONIC PEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL VIRULENCE; CONTROLLED STUDY; CROSS RESISTANCE; DRUG EXPOSURE; FEMALE; IN VITRO STUDY; INNATE IMMUNITY; MASS SPECTROMETRY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MOUSE; MUTANT; NONHUMAN; PROTEOMICS; SEPSIS; STAPHYLOCOCCUS AUREUS; WHOLE GENOME SEQUENCING; ANIMAL; BAGG ALBINO MOUSE; DISEASE MODEL; DRUG EFFECTS; DRUG TOLERANCE; GENETIC SELECTION; HUMAN; MICROBIOLOGY; PATHOGENICITY; PATHOLOGY; STAPHYLOCOCCUS INFECTION; VIRULENCE; VIRUS CULTURE;

ANIMALS; ANTI-INFECTIVE AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, BACTERIAL; DRUG TOLERANCE; FEMALE; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICE, INBRED BALB C; SELECTION, GENETIC; SEPSIS; SERIAL PASSAGE; STAPHYLOCOCCAL INFECTIONS; VIRULENCE;

EID: 85014553580     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkw381     Document Type: Article

References (60)

1. WHO. Antimicrobial Resistance: Global Report on Surveillance. http://www.who.int/drugresistance/documents/surveillancereport/en/.
2. van der Does AM, Bergman P, Agerberth B et al. Induction of the human cathelicidin LL-37 as a novel treatment against bacterial infections. J Leukoc Biol 2012; 92: 735-42.
3. Hancock RE, Sahl HG. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat Biotechnol 2006; 24: 1551-7.
4. Wang G, Li X, Wang Z. APD3: the antimicrobial peptide database as a tool for research and education. Nucleic Acids Res 2016; 44: D1087-93.
5. Epand RM, Walker C, Epand RF et al. Molecular mechanisms of membrane targeting antibiotics. Biochim Biophys Acta 2016; 1858: 980-7.
6. Ghosh A, Kar RK, Jana J et al. Indolicidin targets duplex DNA: structural and mechanistic insight through a combination of spectroscopy and microscopy. ChemMedChem 2014; 9: 2052-8.
7. Fox JL. Antimicrobial peptides stage a comeback. Nat Biotechnol 2013; 31: 379-82.
8. Nell MJ, Tjabringa GS, Wafelman AR et al. Development of novel LL-37 derived antimicrobial peptides with LPS and LTA neutralizing and antimicrobial activities for therapeutic application. Peptides 2006; 27: 649-60.
9. Malanovic N, Leber R, Schmuck M et al. Phospholipid-driven differences determine the action of the synthetic antimicrobial peptide OP-145 on Gram-positive bacterial and mammalian membrane model systems. Biochim Biophys Acta 2015; 1848: 2437-47.
10. Nizet V, Ohtake T, Lauth X et al. Innate antimicrobial peptide protects the skin from invasive bacterial infection. Nature 2001; 414: 454-7.
11. Midorikawa K, Ouhara K, Komatsuzawa H et al. Staphylococcus aureus susceptibility to innate antimicrobial peptides, β-defensins and CAP18, expressed by human keratinocytes. Infect Immun 2003; 71: 3730-9.
12. Velden WJ, van Iersel TM, Blijlevens NM et al. Safety and tolerability of the antimicrobial peptide human lactoferrin 1-11 (hLF1-11). BMC Med 2009; 7: 44.
13. Bell G, Gouyon PH. Arming the enemy: the evolution of resistance to self-proteins. Microbiology 2003; 149: 1367-75.
14. Lofton H, Pranting M, Thulin E et al. Mechanisms and fitness costs of resistance to antimicrobial peptides LL-37, CNY100HL and wheat germ histones. PLoS One 2013; 8: e68875.
15. Perron GG, ZasloffM, Bell G. Experimental evolution of resistance to an antimicrobial peptide. Proc Biol Sci 2006; 273: 251-6.
16. Hale JD, Hancock RE. Alternative mechanisms of action of cationic antimicrobial peptides on bacteria. Expert Rev Anti Infect Ther 2007; 5: 951-9.
17. Nizet V. Antimicrobial peptide resistance mechanisms of human bacterial pathogens. Curr Issues Mol Biol 2006; 8: 11-26.
18. Habets MG, Brockhurst MA. Therapeutic antimicrobial peptides may compromise natural immunity. Biol Lett 2012; 8: 416-8.
19. Klein E, Smith DL, Laxminarayan R. Hospitalizations and deaths caused by methicillin-resistant Staphylococcus aureus, United States, 1999-2005. Emerg Infect Dis 2007; 13: 1840-6.
20. Chambers HF, Deleo FR. Waves of resistance: Staphylococcus aureus in the antibiotic era. Nat Rev Microbiol 2009; 7: 629-41.
21. Cosgrove SE, Qi Y, Kaye KS et al. The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges. Infect Control Hosp Epidemiol 2005; 26: 166-74.
22. Diep BA, Gill SR, Chang RF et al. Complete genome sequence of USA300, an epidemic clone of community-acquired meticillin-resistant Staphylococcus aureus. Lancet 2006; 367: 731-9.
23. Kennedy AD, Otto M, Braughton KR et al. Epidemic communityassociated methicillin-resistant Staphylococcus aureus: recent clonal expansion and diversification. Proc Natl Acad Sci USA 2008; 105: 1327-32.
24. Baba T, Bae T, Schneewind O et al. Genome sequence of Staphylococcus aureus strain Newman and comparative analysis of staphylococcal genomes: polymorphism and evolution of two major pathogenicity islands. J Bacteriol 2008; 190: 300-10.
25. Fey PD, Endres JL, Yajjala VK et al. A genetic resource for rapid and comprehensive phenotype screening of nonessential Staphylococcus aureus genes. MBio 2013; 4: e00537-12.
26. Dorschner RA, Lopez-Garcia B, Peschel A et al. The mammalian ionic environment dictates microbial susceptibility to antimicrobial defense peptides. FASEB J 2006; 20: 35-42.
27. Simon JH, Becker WM. A polyethylene glycol/dextran procedure for the isolation of chromatin proteins (histones and nonhistones) from wheat germ. Biochim Biophys Acta 1976; 454: 154-71.
28. Pasupuleti M, Walse B, Svensson B et al. Rational design of antimicrobial C3a analogues with enhanced effects against staphylococci using an integrated structure and function-based approach. Biochemistry 2008; 47: 9057-70.
29. Vizcaino JA, Csordas A, Del-Toro N et al. 2016 update of the PRIDE database and its related tools. Nucleic Acids Res 2016; 44: D447-56.
30. Wiegand I, Hilpert K, Hancock RE. Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC) of antimicrobial substances. Nat Protoc 2008; 3: 163-75.
31. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically-Ninth Edition: Approved Standard M07-A9. CLSI, Wayne, PA, USA, 2012.
32. Baumert N, von EiffC, SchaaffF et al. Physiology and antibiotic susceptibility of Staphylococcus aureus small colony variants. Microb Drug Resist 2002; 8: 253-60.
33. B, urges Staphylococcus aureus to thicken the cell wall and to resist β-lactams. Biochem Biophys Res Commun 2001; 288: 385-9.
34. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009; 4: 44-57.
35. Huang da W, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res 2009; 37: 1-13.
36. Gould J. GENE.E: Interact with GENE-E fromR. http://www.broadinstitute. org/cancer/software/GENE-E.
37. Kawasaki H, Iwamuro S. Potential roles of histones in host defense as antimicrobial agents. Infect Disord Drug Targets 2008; 8: 195-205.
38. Agerberth B, Lee JY, Bergman T et al. Amino acid sequence of PR-39. Isolation from pig intestine of a new member of the family of prolinearginine-rich antibacterial peptides. Eur J Biochem 1991; 202: 849-54.
39. Glaser R, Becker K, von EiffC et al. Decreased susceptibility of Staphylococcus aureus small-colony variants toward human antimicrobial peptides. J Invest Dermatol 2014; 134: 2347-50.
40. Andersson DI, Hughes D, Kubicek-Sutherland JZ. Mechanisms and consequences of bacterial resistance to antimicrobial peptides. Drug Resist Updat 2016; 26: 43-57.
41. Samuelsen O, Haukland HH, Kahl BC et al. Staphylococcus aureus small colony variants are resistant to the antimicrobial peptide lactoferricin B. J Antimicrob Chemother 2005; 56: 1126-9.
42. Sutcliffe IC, Russell RR. Lipoproteins of Gram-positive bacteria. J Bacteriol 1995; 177: 1123-8.
43. Somerville GA, Proctor RA. At the crossroads of bacterial metabolism and virulence factor synthesis in Staphylococci. Microbiol Mol Biol Rev 2009; 73: 233-48.
44. Kinkel TL, Roux CM, Dunman PM et al. The Staphylococcus aureus SrrAB two-component system promotes resistance to nitrosative stress and hypoxia. MBio 2013; 4: e00696-13.
45. Mishra NN, McKinnell J, Yeaman MR et al. In vitro cross-resistance to daptomycin and host defense cationic antimicrobial peptides in clinical methicillin-resistant Staphylococcus aureus isolates. Antimicrob Agents Chemother 2011; 55: 4012-8.
46. Beceiro A, Tomas M, Bou G. Antimicrobial resistance and virulence: a successful or deleterious association in the bacterial world? Clin Microbiol Rev 2013; 26: 185-230.
47. Andersson DI, Hughes D. Antibiotic resistance and its cost: is it possible to reverse resistance? Nat Rev Microbiol 2010; 8: 260-71.
48. Cheung AL, Bayer AS, Zhang G et al. Regulation of virulence determinants in vitro and in vivo in Staphylococcus aureus. FEMS Immunol Med Microbiol 2004; 40: 1-9.
49. Graves SF, Kobayashi SD, DeLeo FR. Community-associated methicillinresistant Staphylococcus aureus immune evasion and virulence. J Mol Med (Berl) 2010; 88: 109-14.
50. Liu GY, Essex A, Buchanan JT et al. Staphylococcus aureus golden pigment impairs neutrophil killing and promotes virulence through its antioxidant activity. J Exp Med 2005; 202: 209-15.
51. Lofton H, Anwar N, Rhen M et al. Fitness of Salmonella mutants resistant to antimicrobial peptides. J Antimicrob Chemother 2015; 70: 432-40.
52. Strandberg KL, Richards SM, Tamayo R et al. An altered immune response, but not individual cationic antimicrobial peptides, is associated with the oral attenuation of Ara4N-deficient Salmonella enterica serovar Typhimurium in mice. PLoS One 2012; 7: e49588.
53. Kluytmans J, van Belkum A, Verbrugh H. Nasal carriage of Staphylococcus aureus: epidemiology, underlying mechanisms, and associated risks. Clin Microbiol Rev 1997; 10: 505-20.
54. von EiffC, Becker K, Machka K et al. Nasal carriage as a source of Staphylococcus aureus bacteremia. Study Group. N Engl J Med 2001; 344: 11-6.
55. Zanger P, Nurjadi D, Vath B et al. Persistent nasal carriage of Staphylococcus aureus is associated with deficient induction of human β-defensin 3 after sterile wounding of healthy skin in vivo. Infect Immun 2011; 79: 2658-62.
56. Kubicek-Sutherland JZ, HeithoffDM, Ersoy SC et al. Host-dependent induction of transient antibiotic resistance: A prelude to treatment failure. EBioMedicine 2015; 2: 1169-78.
57. Thulin E, Sundqvist M, Andersson DI. Amdinocillin (mecillinam) resistance mutations in clinical isolates and laboratory-selected mutants of Escherichia coli. Antimicrob Agents Chemother 2015; 59: 1718-27.
58. Young BC, Golubchik T, Batty EM et al. Evolutionary dynamics of Staphylococcus aureus during progression from carriage to disease. Proc Natl Acad Sci USA 2012; 109: 4550-5.
59. Liu CM, Price LB, Hungate BA et al. Staphylococcus aureus and the ecology of the nasal microbiome. Sci Adv 2015; 1: e1400216.
60. Brown AF, Leech JM, Rogers TR et al. Staphylococcus aureus colonization: modulation of host immune response and impact on human vaccine design. Front Immunol 2014; 4: 507.